期刊文献+

上海市黄浦区新生儿血源乙型肝炎疫苗免疫后28年效果随访 被引量:3

Efficacy of Immunization of Plasma-derived Hepatitis B Vaccine 28 Years after Vaccination of Newborns in Huangpu District,Shanghai
原文传递
导出
摘要 目的了解新生儿血源乙型肝炎(乙肝)疫苗(HepB)接种的长期免疫效果和加强免疫的必要性。方法对黄浦区1986年出生并全程接种血源HepB的对象隔年随访,采血检测和分析乙肝表面抗原(HBs Ag)携带率、乙肝表面抗体(Anti-HBs)阳性率、乙肝核心抗体(Anti-HBc)阳性率。结果在28年14次随访的213~988例样本中,HBsAg携带率在0.19%~0.98%之间,未随免疫时间延长出现上升趋势(χ~2=0.870,P=0.351);Anti-HBc阳性率在0.96%~3.40%之间,随免疫时间延长未呈现下降趋势(χ~2=3.457,P=0.063);Anti-HBs阳性率在20.11%~89.72%之间,随免疫时间延长呈现下降趋势(χ~2=797.206,P〈0.001)。结论新生儿使用血源Hep B免疫有较好的持久性,免疫后28年无需加强免疫。 Objective To evaluate the long-term effect of domestic plasma-derived hepatitis B vaccine( p Hep B) in newborns,and to determine whether a booster dose is needed.Methods We followed up subjects who were born in 1986 and immunized with p Hep B in Huangpu district of Shanghai every two years,and determined carriage rates of hepatitis B surface antigen( Hbs Ag) and positivity rates of hepatitis B surface antibody( Anti-HBc) and hepatitis B core antibody( Anti-HBc).Results Among 213 of988 subjects receiving 14 follow-up assessments over 28-years,HBs Ag carriage rates were 0.19%-0.98%,without a significant increase over time( χ~2= 0.870,P = 0.351).Anti-HBc positive rates were0.96%-3.40% without a significant decrease over time( χ~2= 3.457,P = 0.063).Anti-HBs positive rates were 20.11%-89.72%,with a significant decrease over time( χ~2= 797.206,P 0.001).Conclusions The p Hep B had good immune persistence following vaccination of newborns.A booster immunization is not necessary 28 years after primary immunization.
出处 《中国疫苗和免疫》 北大核心 2016年第3期278-280,277,共4页 Chinese Journal of Vaccines and Immunization
基金 上海市黄浦区卫计系统学科带头人培养项目"黄浦区血源乙型肝炎疫苗免疫长期效果研究"(编号:HPXD-03)
关键词 血源乙肝疫苗 长期免疫效果 Plasma-derived Hepatitis B Vaccine Long-term Immune Effect
  • 相关文献

参考文献2

二级参考文献11

  • 1吴维寿,孙超美,姜铭波,张国华,周宁,欧阳佩英,汪萱怡,徐志一.乙型肝炎免疫预防持续效果探讨(18年随访结果)[J].中国计划免疫,2005,11(3):204-207. 被引量:34
  • 2黄名军 傅廷源 等.乙型肝炎病毒感染流行水平的调查[J].上海预防医学,1989,1:16-17.
  • 3Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine [ J ]. Vaccine, 2000,18:57 - 67.
  • 4Bantvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B:the role of vaccine immunogenicity in immune memory [ J ]. Vaccins, 2001,19:877 - 885.
  • 5Banatvala J, van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine, 2000,19 : 877-885.
  • 6Wainwright RB, McMahon BJ, Bulkow LR, et al. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: seven-year results. Arch Intern Med, 1991,151 : 1634-1636.
  • 7Coursaget P, Leboulleux D, Soumare M, et al. Twelve-year follow- up study of hepatitis B immunization of Senegalese infants. J Hepatol, 1994,21:250-254.
  • 8But DY, Lai CL, Lim WL, et al. Twenty-two years follow-up of aprospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine, 2008,26: 6587-6591.
  • 9Roffolini T, Mele A, Tosti ME, et al. The impact of the hepatitis B mass immunisation cam-paign on the incidence and risk factors of acute henatitis B in Italv. J Henatol. 2000.33 (6), 980-985.
  • 10林曦敏,徐志一,欧阳佩英,吴维寿,邵志萍,应庆茹,曹惠霖,刘崇柏.新生儿乙型肝炎疫苗免疫的远期效果考核(11年随访结果)[J].中华流行病学杂志,1999,20(3):174-177. 被引量:57

共引文献15

同被引文献39

引证文献3

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部